Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JL19001 in Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07603479Phase 1Recruiting
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
- Start
- Jun 2026
- Primary completion
- May 2030
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of JL19001 in solid tumor and non-Hodgkin lymphoma (NHL) (6 arms), sponsored by Jecho Biopharmaceuticals Co., Ltd. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose up to 3 years and 3 more. Started Jun 2026; status: recruiting.
02
Drugs
JL19001
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07603479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07603479.